Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: A new strategy for studying the immunologic relatedness of HIV-1

Journal of Virology

Volumn 72, Issue 11, 1998, Pages 9384-9391

  Nyambi, Phillipe N ^a   Gorny, Miroslaw K ^a   Bastiani, Lisa ^a   Van Der Groen, Guido ^b   Williams, Constance ^a   Zolla Pazner, Susan ^a,c  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY; VIRUS ANTIGEN;

ANTIGEN BINDING; ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; EPITOPE MAPPING; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRION;

EID: 0031710046     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.11.9384-9391.1998     Document Type: Article

References (55)

1. Arakelov, S., M. K. Gorny, C. Williams, C. H. Riggin, F. Brady, M. S. Collett, and S. Zolla-Pazner. 1993. Generation of neutralizing anti-B19 parvovirus human monoclonal antibodies from patients infected with human immunodeficiency virus. J. Infect. Dis. 168:580-585.
2. Armstrong, S. J., and N. J. Dimmock. 1996. Varying temperature-dependence of post-attachment neutralization of human immunodeficiency virus type 1 by monoclonal antibodies to gp120: identification of a very early fusion-independent event as a neutralization target. J. Gen. Virol. 77:1397-1402.
3. Armstrong, S. J., T. L. McInerney, L. McLain, B. Wahren, J. Hinkula, M. Levi, and N. J. Dimmock. 1996. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1. J. Gen. Virol. 77:2931-2941.
4. Back, N. K. T., L. Smith, and J. J. Dejong. 1994. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 2:431-438.
5. Barin, F., Y. Lahbabi, L. Buzelay, B. Lejeune, A. Baillou-Beaufils, F. Denis, C. Mathiot, S. M'Boup, V. Vithayasai, U. Dietrich, and A. Goudeau. 1996. Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: an approach for HIV type 1 serological subtyping. AIDS Res. Hum. Retroviruses 12:1279-1289.
6. Bastiani, L., S. Laal, S. Zolla-Pazner, and M. Kim. 1997. Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions. J. Virol. 71:3444-3450.
7. Bjorndal, A., H. Deng, M. Jansson, J. R. Fiore, C. Colognesi, A. Karlsson, J. Albert, G. Scarlatti, D. R. Littman, and E. M. Fenyo. 1997. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71:7478-7487.
8. Bolmstedt, A., S. Olofsson, E. Sjogren-Jansson, S. Jeansson, I. Sjoblom, L. Akerblom, J. S. Hansen, and S. Hu. 1992. Carbohydrate determinant NeuAc-GalB(1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein pg120. J. Gen. Virol. 73:3099-3105.
9. Bou-Habib, D. C., G. Roderiquez, T. Oravecz, P. W. Berman, P. Lusso, and M. A. Norcross. 1994. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68:6006-6013.
10. Broder, C. C., P. L. Earl, D. Long, S. T. Abedon, B. Moss, and R. W. Doms. 1994. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. Proc. Natl. Acad. Sci. USA 91:11699-11703.
11. Capobianchi, M. R., S. Fais, C. Castilletti, M. Gentile, F. Amelglio, and F. Dianzani. 1994. A simple and reliable method to detect cell membrane proteins on infectious human immunodeficiency virus type 1 particles. J. Infect. Dis. 169:886-889.
12. Cecilia, D., V. N. KewalRamani, J. O'Leary, B. Volsky, P. Nyambi, S. Burda, S. Xu, D. R. Littman, and S. Zolla-Pazner. 1998. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J. Virol. 72:6988-6996.
13. Cheng-Mayer, C., T. Shioda, and J. A. Levy. 1991. Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120. J. Virol. 65:6931-6941.
14. Conley, A. J., M. K. Gorny, J. A. Kessler II, L. J. Boots, M. Ossorio-Castro, D. W. Lineberger, E. A. Emini, S. Koenig, C. Williams, and S. Zolla-Pazner. 1994. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J. Virol. 68:6994-7000.
15. Davis, D., M. Stephens, C. Willers, and P. Lachmann. 1990. Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. J. Gen. Virol. 71:2889-2898.
16. Fouts, T. R., J. M. Binley, A. Trkola, J. E. Robinson, and J. P. Moore. 1997. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71:2779-2785.
17. Gelderblom, H. R. 1991. Assembly and morphology of HIV: potential effect of structure on viral function. AIDS 5:617-637.
18. Gorny, M. K., A. J. Conley, S. Karwowska, A. Buchbinder, J. Xu, E. A. Emini, S. Koenig, and S. Zolla-Pazner. 1992. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66:7538-7542.
19. Gorny, M. K., V. Gianakakos, S. Sharpe, and S. Zolla-Pazner. 1989. Generation of human monoclonal antibodies to HIV. Proc. Natl. Acad. Sci. USA 86:1624-1628.
20. Gorny, M. K., J. R. Mascola, Z. R. Israel, T. C. VanCott, C. Williams, P. Balfe, C. Hioe, S. Brodine, S. Burda, and S. Zolla-Pazner. 1998. A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades. AIDS Res. Hum. Retroviruses 14:213-221.
21. Gorny, M. K., J. P. Moore, A. J. Conley, S. Karwowska, J. Sodroski, C. Williams, S. Burda, L. J. Boots, and S. Zolla-Pazner. 1994. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J. Virol. 68:8312-8320.
22. Gorny, M. K., T. C. VanCott, C. Hioe, Z. R. Israel, N. L. Michael, A. J. Conley, C. Williams, J. A. Kessler II, P. Chigurupati, S. Burda, and S. Zolla-Pazner. 1997. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and inter-clade cross-reactivity. J. Immunol. 159:5114-5122.
23. Gorny, M. K., J. Xu, S. Karwowska, A. Buchbinder, and S. Zolla-Pazner. 1993. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150:635-643.
24. Goudsmit, J., C. Debouck, R. H. Meloen, L. Smit, M. Bakker, D. M. Asher, A. V. Wolff, C. J. Gibbs, Jr., and D. C. Gajdusek. 1988. Human immunodeficiency virus type 1 neutralization epilope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc. Natl. Acad. Sci. USA 85:4478-4482.
25. Haigwood, N. L., C. B. Barker, K. W. Higgens, P. V. Skiles, G. K. Moore, K. A. Mann, D. R. Lee, J. W. Eichberg, and K. S. Steimer. 1990. Evidence for neutralizing antibodies directed against conformational epitopes of HIV-1 gp120, p. 313-320. In F. Brown, R. M. Chanock, H. Ginsberg, and R. A. Luner (ed.), Vaccines 90: modern approaches to new vaccines including prevention of AIDS. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
26. Hansen, J. S., C. Nielsen, M. Arendrup, S. Olofsson, L. Mathiesen, J. O. Nielsen, and H. Clausen. 1991. Broadly neutralizing antibodies targeted to mucin-type carbohydrate epitopes of human immunodeficiency virus. J. Virol. 65:6461-6467.
27. Hioe, C. E., S. Xu, P. Chigurupati, S. Burda, C. Williams, M. K. Gorny, and S. Zolla-Pazner. 1997. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int. Immunol. 9:1281-1290.
28. Hwang, S. S., T. J. Boyle, H. K. Lyerly, and B. R. Cullen. 1991. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253:71-74.
29. Israel, Z. R., M. K. Gorny, C. Palmer, J. A. McKeating, and S. Zolla-Pazner. 1997. Prevalence of a V2 epitope in clade B primary isolates and its recognition by sera from HIV-1 infected individuals. AIDS 11:128-130.
30. Janssens, W., L. Heyndrickx, K. Fransen, J. Mitte, M. Peeters, J. N. Nkengasong, P. M. Ndumbe, E. Delaporte, J. Perret, C. Atende, P. Piot, and G. van der Groen. 1994. Genetic and phylogenetic analysis of env subtypes G and H in Central Africa. AIDS Res. Hum. Retroviruses 10:877-879.
31. Karwowska, S., M. K. Gorny, A. Buchbinder, V. Gianakakos, C. Williams, T. Fuerst, and S. Zolla-Pazner. 1992. Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res. Hum. Retroviruses 8:1099-1106.
32. Karwowska, S., M. K. Gorny, S. Culpepper, S. Burda, S. Laal, K. Samanich, and S. Zolla-Pazner. 1993. The similarities and diversity among human monoclonal antibodies to the CD4-binding domain of HIV-1, p. 229-232.In F. Brown, H. S. Sinsberg, and R. Lerner (ed.), Vaccines 93: modern approaches to vaccine including prevention of AIDS. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
33. Louwagie, J., F. E. McCutchan, M. Peeters, T. P. Brennan, E. Sanders-Buell, G. A. Eddy, G. van der Groen, K. Fransen, G.-M. Gershy-Damet, R. Deleys, and D. S. Burke. 1993. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS 7:769-780.
34. Moore, J. P., Y. Cao, J. Leu, L. Qin, B. Korber, and D. D. Ho. 1996. Interand intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70:427-444.
35. Moore, J. P., Y. Cao, L. Qing, Q. J. Sattentau, J. Pyati, R. Koduri, J. Robinson, C. F. Barbas III, D. R. Burton, and D. D. Ho. 1995. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:101-109.
36. Moore, J. P., F. E. McCutchan, S. Poon, J. Mascola, J. Liu, Y. Cao, and D. D. Ho. 1994. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J. Virol. 68:8350-8364.
37. Moore, J. P., Q. Sattentau, R. Wyatt, and J. Sodroski. 1994. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J. Virol. 68:469-484.
38. Moore, J. P., and J. Sodroski. 1996. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70:1863-1872.
39. Myers, G., B. Korber, B. Foley, R. F. Smith, K. Jeang, J. W. Mellors, and A. Wain-Hobson (ed.). 1996. Human retroviruses and AIDS. Theoretical biology and biophysics. Los Alamos National Laboratories, Los Alamos, N. Mex.
40. Nkengasong, J. N., W. Janssens, L. Heyndrickx, K. Fransen, P. M. Ndumbe, J. Motte, A. Leonaers, M. Ngolle, J. Ayuk, P. Piot, and G. van der Groen. 1994. Genetic subtypes of HIV-1 in Cameroon. AIDS 8:1405-1412.
41. Nyambi, P. N., L. Heyndrickx, W. Janssens, F. Daeyaert, P. Lewi, K. Fransen, B. Willems, S. Coppens, K. Vereecken, P. Piot, and G. van der Groen. Identification of specific amino acid motifs and biophenotypic properties among primary HIV-1 group M (subtype A-H) and O isolates belonging to different neutralization clusters. Submitted for publication.
42. Nyambi, P. N., J. Nkengasong, P. Lewi, K. Andries, W. Janssens, K. Fransen, L. Heyndrickx, P. Piot, and G. van der Groen. 1996. Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J. Virol. 70:6235-6243.
43. Nyambi, P. N., J. Nkengasong, M. Peeters, F. Simon, J. Eberle, W. Janssens, K. Fransen, B. Willems, K. Vereecken, L. Heyndrickx, P. Piot, and G. van der Groen. 1995. Reduced capacity of antibodies from patients infected with human immunodeficiency virus type-1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses. J. Infect. Dis. 172:1228-1237.
44. Orentas, R. J., and J. E. K. Hildreth. 1993. Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV. AIDS Res. Hum. Retroviruses. 9:1157-1165.
45. Palker, T. J., M. E. Clark, A. J. Langlois, T. J. Matthews, K. J. Weinhold, R. R. Randall, D. P. Bolognesi, and B. F. Haynes. 1988. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc. Natl. Acad. Sci. USA 85:1932-1136.
46. Palker, T. J., M. E. Clark, A. L. Langlois, T. J. Matthews, K. J. Weinhold, R. R. Randall, D. P. Bolognesi, and G. Haynes. 1988. Type-specific neutralization of HIV with antibodies to env-encoded synthetic peptides. Proc. Natl. Acad. Sci. USA 85:1758-1762.
47. Sattentau, Q. J., and J. P. Moore. 1995. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182:185-196.
48. Shioda, T., J. A. Levy, and C. Cheng-Mayer. 1991. Macrophage and T cell line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 349:167-169.
49. Stamatatos, L., and C. Cheng-Mayer. 1995. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. J. Virol. 69: 6191-6198.
50. Starcich, B., B. Hahn, G. Shaw, P. McNeely, S. Modrow, H. Wolf, E. Parks, W. Parks, S. Josephs, R. Gallo, and F. Wong-Staal. 1986. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 45:637-648.
51. Sullivan, N., Y. Sun, J. Li, W. Hofmann, and J. Sodroski. 1995. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 69:4413-4422.
52. VanCott, T. C., F. R. Bethkes, V. R. Polonis, M. G. Gorny, S. Zolla-Pazner, R. R. Redfield, and D. L. Birx. 1994. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J. Immunol. 153:449-459.
53. Weber, J., E. M. Fenyo, S. Beddows, P. Kaleebu, Å. Björndal, and the WHO Network for HIV Isolation and Characterization. 1996. Neutralization serotypes of human immunodeficiency type 1 field isolates are not predicted by genetic subtype. J. Virol. 70:7827-7832.
54. Zhang, L., C. D. Carruthers, T. He, Y. Huang, V. Cao, G. Wang, B. Hahn, and D. D. Ho. 1997. HIV type 1 subtypes, coreceptor usage, and CCR5 polymorphism. AIDS Res. Hum. Retroviruses 13:1357-1366.
55. Zolla-Pazner, S., J. O'Leary, S. Burda, M. K. Gorny, M. Kim, J. Mascola, and F. McCutchan. 1995. Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. J. Virol. 69:3807-3815.